Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bulcan.2023.06.005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Futibatinib is the only covalent inhibitor of FGFR1-4 to gain regulatory approval in oncology. In this article, we present genomic analyses of tissue biopsies and circulating tumor DNA (ctDNA) from patients with 1 of nearly 20 tumor types treated with futibatinib in the phase I/II FOENIX study.
Patients And Methods: Eligible patients included those with ctDNA samples collected per protocol at baseline and/or progression on futibatinib in the phase Ib portion of the study for FGF/FGFR-altered advanced solid tumors or the phase II portion of the study for FGFR2 fusion/rearrangement-positive cholangiocarcinoma.
Fibroblast growth factor therapies in biliary tract cancers: current and future state.
Expert Opin Investig Drugs
December 2024
Department of Oncology, Case Western Reserve University, Cleveland, OH, USA.
Article Synopsis
- Cholangiocarcinoma is a rare and aggressive cancer with a poor outlook, but recent advances in targeted therapies focus on a specific pathway known as FGFR which is linked to its development.
- Current FGFR-targeted treatments, like pemigatinib and futibatinib, have been approved and show promise, but many patients either don't respond or develop resistance over time.
- Researchers are exploring new FGFR inhibitors to enhance effectiveness and minimize side effects, aiming to improve patient outcomes and quality of life.
Practical Management of Adverse Events Associated With FGFR Inhibitors for Cholangiocarcinoma for the Advanced Practice Provider.
J Adv Pract Oncol
February 2024
National Community Oncology Dispensing Association, Cazenovia, New York.
Article Synopsis
- Cholangiocarcinoma is a bile duct cancer often diagnosed late, leading to poor prognosis, but selective FGFR inhibitors show promise in treating it, especially in cases with specific genetic alterations.
- These FGFR inhibitors can cause side effects like hyperphosphatemia, fatigue, and other gastrointestinal and dermatological issues, which need to be managed proactively to improve treatment adherence and patient outcomes.
- A multidisciplinary care team including various healthcare professionals is essential, with practical guidance provided on managing side effects, considering interactions with other medications or foods, and offering supportive care recommendations for patients.
Plain language summary: an analysis of the safety of futibatinib treatment in people with different types of cancer.
Future Oncol
October 2024
Department of Medicine, Division of Oncology, Massachusetts General Hospital, Boston, MA, USA.
What Is This Summary About?: Researchers combined information from three separate phase 1 and 2 clinical trials, including over 400 people who had one of 33 different cancer types and who all received futibatinib in their clinical trial. This type of study is called a pooled analysis. Futibatinib is taken orally (by mouth) as a tablet and works by reducing the activity of a group of proteins called fibroblast growth factor receptors (FGFRs).
View Article and Find Full Text PDF[Pharmacological characteristics and clinical effectiveness of Futibatinib (Lytgobi Tablets), a covalently-binding, irreversible FGFR1-4 inhibitor].
Nihon Yakurigaku Zasshi
November 2024
Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd.
Article Synopsis
- Futibatinib, a new FGFR inhibitor developed by Taiho Pharmaceutical, was approved in Japan in June 2023 for treating inoperable biliary tract cancer with specific genetic changes after prior chemotherapy.
- This drug works by irreversibly binding to the FGFR receptor, inhibiting cancer cell growth more effectively than earlier FGFR inhibitors.
- In clinical studies, futibatinib demonstrated a 41.7% overall response rate in patients with certain types of bile duct cancer, showing a good safety profile and the potential to treat more cancer types in the future.*
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!